• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Spyre Therapeutics Inc.

    4/22/26 4:00:02 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYRE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    SPYRE THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock, $0.0001 Par Value Per Share

    (Title of Class of Securities)




    00773J202

    (CUSIP Number)
    04/15/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    00773J202


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,319,496.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,319,496.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,319,496.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):
    00773J202


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,319,496.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,319,496.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,319,496.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    00773J202


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,319,496.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,319,496.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,319,496.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SPYRE THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    221 Crescent Street Building 23, Suite 105, Waltham, MA 02453
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Stock, $0.0001 Par Value Per Share (the "Common Stock") of SPYRE THERAPEUTICS, INC. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, $0.0001 Par Value Per Share
    (e)CUSIP Number(s):

    00773J202
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 85,664,811 shares of Common Stock outstanding, as reported in the Issuer's prospectus supplement filed pursuant to Rule 424(b)(5) filed with the Securities and Exchange Commission on April 16, 2026, giving effect to the exercise of the underwriters' option as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 16, 2026. The Master Fund directly holds 4,319,496 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the shares held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares held by the Master Fund.
    (b)Percent of class:

    Perceptive Advisors: 5.0% Mr. Edelman: 5.0% Master Fund: 5.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 4,319,496 Mr. Edelman: 4,319,496 Master Fund: 4,319,496

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 4,319,496 Mr. Edelman: 4,319,496 Master Fund: 4,319,496

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:04/22/2026
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:04/22/2026
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:04/22/2026
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement

    Get the next $SYRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYRE

    DatePrice TargetRatingAnalyst
    4/14/2026$80.00Strong Buy
    Raymond James
    12/18/2025$53.00Outperform
    Mizuho
    12/17/2025$64.00Buy
    Citigroup
    9/26/2025$43.00Buy
    Deutsche Bank
    4/8/2025$45.00Outperform
    Leerink Partners
    3/18/2025$27.00Outperform
    Wolfe Research
    9/4/2024$45.00Outperform
    Wedbush
    7/16/2024Outperform
    Evercore ISI
    More analyst ratings

    $SYRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Sloan Sheldon exercised 8,333 shares at a strike of $27.46 and sold $624,975 worth of shares (8,333 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

    6/3/26 9:32:02 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 units (SEC Form 4)

    4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

    6/3/26 9:31:11 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Burrows Scott L sold $532,937 worth of shares (7,500 units at $71.06) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $14.50 (SEC Form 4)

    4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

    6/3/26 9:30:41 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Spyre Therapeutics with a new price target

    Raymond James initiated coverage of Spyre Therapeutics with a rating of Strong Buy and set a new price target of $80.00

    4/14/26 8:35:35 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Spyre Therapeutics with a new price target

    Mizuho initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $53.00

    12/18/25 9:11:03 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Spyre Therapeutics with a new price target

    Citigroup initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $64.00

    12/17/25 9:29:11 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

    Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for PsA and axSpA Across SKYWAY and SKYLINE trials, planned ‘6 in '26' Phase 2 readouts enabled and on track Preclinical data supporting SPY072 in rheumatic diseases presented at 2026 European Congress of Rheumatology (EULAR) WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more compl

    6/3/26 8:00:00 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation

    DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially

    5/28/26 8:35:00 AM ET
    $ABVX
    $ORKA
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Spyre Therapeutics to Participate in Upcoming June Investor Conferences

    WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference – New YorkDate: Wednesday, June 3, 2026Fireside Time: 12:15 pm ET Event: Goldman Sachs 47th Annual Global Healthcare Conference – MiamiDate: Monday, June 8, 2026Fireside Time: 10:00 am ET Members of the Spyre management team will also host one-on-one investor meetings

    5/26/26 4:10:00 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYRE
    Leadership Updates

    Live Leadership Updates

    View All

    Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab  Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini

    11/7/24 4:05:00 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

    WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years

    10/1/24 8:00:00 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities

    8/7/24 4:05:00 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

    SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

    11/14/24 5:50:33 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

    SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

    11/14/24 4:33:26 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

    SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

    11/14/24 4:05:09 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYRE
    Financials

    Live finance-specific insights

    View All

    Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

    SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 40% and endoscopic improvement of 51% SPY001 was well tolerated with a safety profile consistent with the α4β7 class Recruitment for SKYLINE Part A closed, now enrolling Part B monotherapy and combination cohorts Management will host a conference call today at 8:00 a.m. ET WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibo

    4/13/26 7:00:00 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

    WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre'

    4/10/26 4:05:00 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

    SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies SKYLINE-UC platform study evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis, initiated in May 2025 SKYWAY-RD basket study evaluating SPY072 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) announced, with initiation expected in Q3 2025 Management to host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass., June 1

    6/17/25 7:30:00 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SYRE
    SEC Filings

    View All

    Spyre Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

    6/1/26 4:01:39 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spyre Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

    5/29/26 4:45:58 PM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

    5/5/26 8:05:31 AM ET
    $SYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care